Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …

Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …

Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–
small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors …

PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …

The introduction of HER2-targeted therapy for breast and gastric patients with ERBB2
(HER2) amplification/overexpression has led to dramatic improvements in oncologic …

Using transgenic mouse models, cell line-based functional studies, and clinical specimens,
we show that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive …

BACKGROUND Human epidermal growth factor receptor 2 (HER2) mutations have been
reported in lung adenocarcinomas. Herein, the authors describe the prevalence, clinical …

Purpose HER2 mutations are identified in approximately 2% of non–small-cell lung cancers
(NSCLC). There are few data available that describe the clinical course of patients with …

Treatment decisions for patients with lung cancer have historically been based on tumour
histology. Some understanding of the molecular composition of tumours has led to the …

Lung cancers are characterised by abundant genetic diversity with relatively few recurrent
mutations occurring at high frequency. However, the genetic alterations often affect a …